These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17727474)

  • 1. Value of elastin staining in the assessment of peritoneal implants associated with ovarian serous borderline tumours.
    Stewart CJ; Brennan BA; Crook ML; Russell P
    Histopathology; 2007 Sep; 51(3):313-21. PubMed ID: 17727474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glomeruloid peritoneal implants in ovarian serous borderline tumours--distinction between invasive and non-invasive implants and pathogenesis.
    Lee ES; Leong AS; Kim IS; Kim YS; Lee JH; Cho HY
    Histopathology; 2009 Nov; 55(5):505-13. PubMed ID: 19912356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma.
    Hogg R; Scurry J; Kim SN; Friedlander M; Hacker N
    Gynecol Oncol; 2007 Jul; 106(1):44-51. PubMed ID: 17467045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological evaluation on ovarian serous borderline tumours and their implants].
    Guo L; Lian L; Liu T
    Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):287-90. PubMed ID: 9206182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
    Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calretinin, CD34, and alpha-smooth muscle actin in the identification of peritoneal invasive implants of serous borderline tumors of the ovary.
    Lee ES; Leong AS; Kim YS; Lee JH; Kim I; Ahn GH; Kim HS; Chun YK
    Mod Pathol; 2006 Mar; 19(3):364-72. PubMed ID: 16415795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian serous borderline tumors with noninvasive and invasive peritoneal implants: A case report each.
    Srinivasamurthy BC; Kulandai Velu AR; Krishnan N; Patil AS
    J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ovarian serous cystadenofibromas associated with a low-grade serous carcinoma of the peritoneum.
    Hinson SA; Silva EG; Pinto K
    Ann Diagn Pathol; 2013 Jun; 17(3):302-4. PubMed ID: 22921726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
    Roh MH; Kindelberger D; Crum CP
    Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ovarian serous tumors of limited malignancy and invasive peritoneal implants. Review of the literature].
    Fondrinier E; Seince N; Verriele V; Lorimier G; Gamelin E
    Contracept Fertil Sex; 1999 Nov; 27(11):780-4. PubMed ID: 10609410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
    McKenney JK; Soslow RA; Longacre TA
    Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bilateral micropapillary serous carcinoma of the ovary: a case report.
    Gupta R; Singh S; Nigam S
    Arch Gynecol Obstet; 2007 May; 275(5):401-4. PubMed ID: 17031658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian psammocarcinoma with peritoneal implants.
    Cobellis L; Pezzani I; Cataldi P; Bome A; Santopietro R; Petraglia F
    Eur J Obstet Gynecol Reprod Biol; 2003 Apr; 107(2):217-9. PubMed ID: 12648875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.